The use of an adjuvant system improves innate and adaptive immune response when associated with a Leishmania (Viannia) braziliensis antigen in a vaccine candidate against L. (Leishmania) infantum infection.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorMathias, Fernando Augusto Siqueira-
Autor(es): dc.creatorOstolin, Thais Lopes Valentim Di Paschoale-
Autor(es): dc.creatorReis, Levi Eduardo Soares-
Autor(es): dc.creatorCardoso, Jamille Mirelle de Oliveira-
Autor(es): dc.creatorBrito, Rory Cristiane Fortes de-
Autor(es): dc.creatorSoares, Rodrigo Dian de Oliveira Aguiar-
Autor(es): dc.creatorRoatt, Bruno Mendes-
Autor(es): dc.creatorVieira, Paula Melo de Abreu-
Autor(es): dc.creatorReis, Alexandre Barbosa-
Data de aceite: dc.date.accessioned2025-08-21T15:28:21Z-
Data de disponibilização: dc.date.available2025-08-21T15:28:21Z-
Data de envio: dc.date.issued2023-10-10-
Data de envio: dc.date.issued2023-10-10-
Data de envio: dc.date.issued2022-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/17549-
Fonte completa do material: dc.identifierhttps://doi.org/10.3390/vaccines11020395-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1016012-
Descrição: dc.descriptionBackground: The adjuvants’ optimal dose and the administration route can directly influence the epitope recognition patterns and profiles of innate response. We aimed to establish the effect and the optimal dose of adjuvant systems for proposing a vaccine candidate to be employed with Leishmania (Viannia) braziliensis. Methods: We evaluated the adjuvants saponin (SAP), monophosphoryl lipid A (MPL) and resiquimod (R-848) isolated and combined as adjuvant systems in a lower dose corresponding to 25%, 33%, and 50% of each adjuvant total dose. Male outbred BALB/c mice were divided into 13 groups, SAP, MPL, and R-848 isolated, and the adjuvant systems SAP plus MPL (SM), SAP plus R-848 (SR), and MPL plus R-848 (MR). Results: SM50 increased levels of all chemokines analyzed and TNF production, while it presented an increased inflammatory cell infiltrate in the skin with macrophage recruitment. Thus, we proposed a vaccine candidate employing L. (V.) braziliensis antigen associated with the SM adjuvant system against experimental L. (Leishmania) infantum challenge. We observed a significant increase in the frequency of cells expressing the central and effector memory CD4+ T cells phenotype in immunized mice with the LBSM50. In the liver, there was a decreased parasite load when mice received LBSM50. Conclusions: When combined with L. (V.) braziliensis antigen, SM50 increases TNF and IFN-γ, which generates central and effector memory CD4+ T cells. Therefore, using an adjuvant system can promote an effective innate immune response with the potential to compose future vaccines.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsaberto-
Direitos: dc.rightsThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.-
Palavras-chave: dc.subjectAdjuvants-
Palavras-chave: dc.subjectAdjuvant system-
Palavras-chave: dc.subjectSaponin-
Palavras-chave: dc.subjectMonophosphoryl lipid A-
Palavras-chave: dc.subjectResiquimod-
Título: dc.titleThe use of an adjuvant system improves innate and adaptive immune response when associated with a Leishmania (Viannia) braziliensis antigen in a vaccine candidate against L. (Leishmania) infantum infection.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.